FDA Granted LM-108 Orphan Drug Designations for Cancer Treatments

December 18^th, 2023 - LaNova Medicines Ltd. announced that its new drug candidate LM-108 (anti-CCR8 monoclonal antibody) has been granted Orphan Drug Designation for the treatment of pancreatic cancer by the FDA in December 2023.  This is another milestone after LM-108 received Fast Track Designation from the FDA for the treatment of NSCLC in April 2023. 

About CCR8:

CCR8 (chemokine receptor 8) is a member of the chemokine receptor subfamily under the G protein-coupled receptor (GPCR) family. Previous studies revealed that the expression of CCR8 is low in peripheral blood cells and normal tissues, but is specifically upregulated in tumor-infiltrating Tregs in multiple cancers including breast cancer, colorectal cancer, and lung cancer. Anit-CCR8 antibodies can selectively mediate the depletion of tumor-infiltrating Tregs, thereby enhancing the anti-tumor immune response and inhibiting tumor growth.